← All companies

EVMN

Evommune, Inc.

EVMN NYSE Pharmaceutical Preparations EDGAR ↗

$11.59

+0.34 +3.02%

Key statistics

from XBRL data in SEC filings

Market cap

$417M

Revenue (TTM)

$13.0M

Net income (TTM)

-$68.9M

EPS (TTM)

$-11.22

P/E ratio

—

Dividend yield

—

Free cash flow

-$76.7M

Cash

$48.3M

Total assets

$322M

Gross margin

—

52-week range

$10.47 – $33.20

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Regulation FD disclosure Jul 30, 2026 8-K Regulation FD disclosure; Other events Jun 29, 2026 8-K Shareholder vote results Jun 2, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release); Regulation FD disclosure May 7, 2026 8-K Regulation FD disclosure Apr 13, 2026 10-K Fiscal year ended 2025-12-31 Mar 5, 2026 8-K Results of operations (earnings release) Mar 5, 2026 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Feb 13, 2026 8-K Regulation FD disclosure Feb 10, 2026 10-Q Quarter ended 2025-09-30 Dec 11, 2025 8-K Results of operations (earnings release) Dec 11, 2025 8-K Amended charter or bylaws Nov 7, 2025

Other filings

SCHEDULE 13G Jul 16, 2026 4 PRIMARY DOCUMENT Jul 10, 2026 4 PRIMARY DOCUMENT Jul 8, 2026 424B3 Jun 29, 2026 4 PRIMARY DOCUMENT Jun 24, 2026 4 PRIMARY DOCUMENT Jun 24, 2026 4 PRIMARY DOCUMENT Jun 24, 2026 144 Jun 22, 2026 4 PRIMARY DOCUMENT Jun 3, 2026 4 PRIMARY DOCUMENT Jun 3, 2026 4 PRIMARY DOCUMENT Jun 3, 2026 4 PRIMARY DOCUMENT Jun 3, 2026 4 PRIMARY DOCUMENT Jun 3, 2026 144 Jun 2, 2026 424B3 Jun 2, 2026 4 PRIMARY DOCUMENT Jun 1, 2026 4 PRIMARY DOCUMENT Jun 1, 2026 144 Jun 1, 2026 144 Jun 1, 2026 144 May 28, 2026 144 May 28, 2026 424B3 May 7, 2026 EFFECT Apr 24, 2026 424B3 Apr 24, 2026 CORRESP Apr 22, 2026 UPLOAD Apr 22, 2026 ARS Apr 21, 2026